Delving into the Latest Updates on Laboratorio Varifarma SA with Synapse

概览

疾病领域	数量

肿瘤	2
血液及淋巴系统疾病	2
感染	1

排名前五的药物类型	数量

生物类似药	4
集落刺激因子	2
干扰素	1
白细胞介素	1

排名前五的靶点	数量

IFNAR(干扰素α/β受体复合体)	1
EPO receptor(促红细胞生成素受体)	1
CSF-3R(巨噬细胞集落刺激因子3受体)	1
IL-2R(白细胞介素-2受体)	1

关联

4

项与 Laboratorio Varifarma SA 相关的药物

Interferon alpha-2b biosimilar(Laboratorio Varifarma SA)

干扰素α-2b生物类似药(Laboratorio Varifarma SA)

靶点

IFNAR

作用机制

IFNAR激动剂 [+2]

在研机构

Laboratorio Varifarma SA

原研机构

Laboratorio Varifarma SA

在研适应症

尖锐湿疣 [+3]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

阿根廷

首次获批日期2014-01-01

Interleukin-2 biosimilar(Laboratorio Varifarma SA)

重组人白细胞介素-2生物类似药(Laboratorio Varifarma SA)

靶点

IL-2R

作用机制

IL-2R激动剂 [+1]

在研机构

Laboratorio Varifarma SA

原研机构

Laboratorio Varifarma SA

在研适应症

肿瘤

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

阿根廷

首次获批日期2011-01-01

Epoetin alfa biosimilar(Laboratorio Varifarma SA)

阿法依伯汀生物类似药(Laboratorio Varifarma SA)

靶点

EPO receptor

作用机制

EPO receptor激动剂

在研机构

Laboratorio Varifarma SA

原研机构

Laboratorio Varifarma SA

在研适应症

贫血

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区-

首次获批日期-

100 项与 Laboratorio Varifarma SA 相关的临床结果

登录后查看更多信息

0 项与 Laboratorio Varifarma SA 相关的专利（医药）

登录后查看更多信息

1

项与 Laboratorio Varifarma SA 相关的文献（医药）

2021-02-09·Blood Advances2区 · 医学

ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project

2区 · 医学

Article

作者: Marino, Dario ; De Souza, Carmino Antonio ; Skrypets, Tetiana ; Federico, Massimo ; Prates, Maria Virginia ; Ko, Young Hyeh ; Cabrera, Maria Elena ; Laszlo, Daniele ; Chiattone, Carlos ; Spina, Michele ; Chiappella, Annalisa ; Ferreri, Andrés J. M. ; Stelitano, Caterina ; Shustov, Andrei ; Bobillo, Sabela ; Vose, Julie M. ; Bellei, Monica ; Manni, Martina ; Horwitz, Steven M. ; Radford, John A. ; Civallero, Monica

AbstractAnaplastic lymphoma kinase–negative anaplastic large cell lymphoma (ALK– ALCL) is an aggressive neoplasm of T-cell/null-cell lineage. The T-Cell Project is a global prospective cohort study that consecutively enrolled patients newly diagnosed with peripheral T-cell lymphoma, registered through a centralized computer database between September 2006 and February 2018. Of 1553 validated cases from 74 sites in 13 countries worldwide, 235 were reported as ALK– ALCL. The median age at diagnosis was 54 years (range, 18-89 years), with a male predominance (62%). Stage III to IV disease was identified in 71% of patients, bulky disease and bone marrow involvement were uncommon, and 66% of patients presented with a low (0-1) International Prognostic Index score. Of all treated patients, 85% received multiagent initial chemotherapy, and 8% were consolidated with autologous hematopoietic cell transplantation. The initial overall and complete response rates were 77% and 63%, respectively. After a median follow-up of 52 months (95% confidence interval [CI], 41-63), the median progression-free survival (PFS) and overall survival (OS) were 41 months (95% CI, 17-62) and 55 months (95% CI, 36-75), respectively. The 3- and 5-year PFS rates were 52% and 43%, and the 3- and 5-year OS rates were 60% and 49%. Treatments containing both anthracycline and etoposide were associated with superior OS (P = .05) but not PFS (P = .18). In this large prospective cohort study, outcomes comparable to those previously reported in the retrospective International Peripheral T-Cell Lymphoma Project were observed. The study underscores the need for introducing novel platforms for ALK– ALCL and establishes a benchmark for future clinical trials. This trial was registered at www.clinicaltrials.gov as #NCT01142674.

100 项与 Laboratorio Varifarma SA 相关的药物交易

登录后查看更多信息

100 项与 Laboratorio Varifarma SA 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

4

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

阿法依伯汀生物类似药(Laboratorio Varifarma SA) ( EPO receptor )	贫血更多	批准上市
非格司亭生物类似药(Laboratorio Varifarma SA) ( CSF-3R )	中性粒细胞减少更多	批准上市
重组人白细胞介素-2生物类似药(Laboratorio Varifarma SA) ( IL-2R )	肿瘤更多	批准上市
干扰素α-2b生物类似药(Laboratorio Varifarma SA) ( IFNAR )	丙型肝炎更多	批准上市